Paolo Tarantino: Why was IMpassion132 negative?
Daniel Stover, Medical Oncologist and Computational Biologist at Ohio State University Comprehensive Cancer Center, shared a post by Paolo Tarantino, on X:
“Disappointing that addition of immunotherapy did not benefit rapid relapse.
Thanks to Sara Tolaney for highlighting Stover Lab work showing primary TNBC that develop rapid relapse highly immune suppressed, perhaps foreshadowing IMpassion132 results.” .
Quoting Paolo Tarantino’s post:
“Why was IMpassion132 negative? And what’s the path forward for improving outcomes in early recurrent TNBC? Great discussion by Sara Tolaney, recapitulating the current status and future hopes for one of the most challenging presentations of breast cancer.”
Source: Daniel Stover/X and Paolo Tarantino/X
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer.
Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023